Federal Circuit Rules For Bristol-Myers In Repligen Patent Suit
The U.S. Court of Appeals for the Federal Circuit has dealt biotech company Repligen a setback, ruling in favor of Bristol-Myers Squibb Co. in a dispute over the ownership of a...To view the full article, register now.
Already a subscriber? Click here to view full article